Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI
The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth.
To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market
here has been an increased focus of players in the market to offer
vaccines, which can augment the market size in the forecast period. For
instance, in March 2022, Japan launched a new center, with a
budget of US$ 1.6 Billion, to support vaccine and drug projects as a part
of a larger scheme to tackle infectious diseases. SCARDA will be in charge of
establishing a flagship R&D site for innovative collaborations and
controlling funds for R&D projects.
Awareness campaigns are expected to play important role in driving the
market during the forecast period. For instance, the ‘See C. diff’ campaign, launched
by Peggy Lillis Foundation in December 2020, attained its objective by
reaching more than 250,000 Americans. The organization launched the ‘See C.
diff’ to commemorate C.diff Awareness Month in 2019, and reached about 80,000
people.
The launch of new vaccines in the market is another vital factor driving
the market during the forecast period. For instance, in August 2021,
Huvepharma Canada Corporation Inc. launched a new vaccine that has been shown
to be effective against necrotic enteritis (NE) due to Clostridium perfringens
type A in broiler chickens.
Clostridium is a genus of bacteria that includes many different species,
some of which can cause serious infections in humans, such as tetanus,
botulism, and gas gangrene. The Clostridium Testing infections is typically made
based on clinical symptoms, laboratory tests, and imaging studies.
Key Takeaways from the Market Study:
- The
immunoassays technology is expected to dominate the global clostridium
diagnostics market at a CAGR of 11.6% during 2022-2032
- The clostridium
diagnostics market in the U.S is anticipated to display a CAGR of 11.8%
during the forecast period
- The U.K
clostridium diagnostics market is predicted to hold a market value
worth US$ 330 Million by 2032
- The Japanese
clostridium diagnostics market is estimated at a CAGR of 11.1% during the
forecast period.
“Growing launch of new vaccines by various players of the market along
with the increasing popularity of awareness campaigns as a useful tool for
market growth is expected to play a significant role in driving the market
during the forecast period,” says an FMI analyst.
Competition Analysis
- Abbott
Laboratories
- F. Hoffmann
La-Roche AG
- Siemens AG
- Becton,
Dickinson & Company
- Beckman Coulter
Inc.
- Sysmex India
Pvt. Ltd.
- Thermo Fisher
Scientific Inc.
- Fujirebio US
Inc.
- BioMerieux S.A
- Diazyme
Laboratories Inc.
Key Segments Profiled In The Global Clostridium Diagnostics Market
Clostridium Diagnostics Market by Technology:
- Immunoassays-based
Clostridium Diagnostics
- Molecular
Clostridium Diagnostics
Clostridium Diagnostics Market by End User:
- Clostridium
Diagnostics in Hospitals
- Clostridium
Diagnostics in Government Diagnostics Laboratories
- Clostridium
Diagnostics in Independent Laboratories
Clostridium Diagnostics Market by Product:
- Clostridium
Difficile Diagnostics
- Clostridium
Perfringens Diagnostics
- Clostridium
Botulinum Diagnostics
- Clostridium
Tetani Diagnostics
- Clostridium
Sordell Diagnostics
Comments
Post a Comment